News

The research saw that new-onset full-thickness macular holes (FTMHs), especially those resulting from blunt ocular trauma, might close spontaneously without the need for a surgical intervention.

Cindy Cai, MD, shared insights from her presentation from ASRS 2023 on "Health disparities in lapses in diabetic retinopathy care" with Sheryl stevenson, our Group Editorial Director.

In presentations at the ASRS 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

During presentations at the ASRS 41st Annual Meeting in Seattle, Apellis noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis, and no events were reported in clinical trials.

Michael Ip, MD, shared his perspective on the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event and why he thinks they are valuable topics to understand and review for retina specialists.

Diana Do, MD, professor of ophthalmology and vice chair of clinical affairs at the Byers Eye Institute at Stanford University, spoke with our team about the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular edema at the 2023 ASRS meeting in Seattle, Washington.

This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.

In a presentation at the ASRS 41st Annual Meeting in Seattle, Diana Do, MD, said the PHOTON study demonstrated the potential aflibercept 8 mg could have in reducing the treatment burden for patients.

RGX-314, an investigational formulation being developed in collaboration with AbbVie, may be a potential one-time treatment for nAMD, diabetic retinopathy, and other chronic retinal conditions.

Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.

At the 2023 ASRS meeting in Seattle, Washington, Carl Danzig, MD, caught up with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy.

Aaron Lee, MD, shared how research and new techniques are expanding the options for deep learning in ophthalmology. He spoke with our team at the 2023 ASRS meeting in Seattle, Washington to share more about this research.

The company announced at the ASRS annual meeting in Seattle the phase 2 Dose Expansion (N=50) initial interim efficacy and safety data presentation expected at medical conference in H1 2024.

Jennifer I. Lim, MD, FARVO, FASRS shared insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis" with our team.

Lim and colleagues conducted a retrospective study to establish the normalized NBFI using OCTA and test if that index is sufficiently sensitive for detecting early DR.

The American Society of Retina Specialists is hosting its annual meeting this year in Seattle, Washington. Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.

Detrimental effects of IVB may not be recognized at an early age, which underscores the importance of following these children over time.

With this funding, the DISCOVER study will evaluate the safety and tolerability of three doses of AXT107 in patients with wet AMD.

Using automated methods to determine the visual acuity showed robust performance in predicting visual impairment.

APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy.

THR-149 is being evaluated in a Phase 2 clinical trial as a potential treatment for diabetic macular edema, which is expected to readout topline results by the end of this year.

The results of this study demonstrated the good safety and tolerability of HLX04-O.

Going forward, sozinibercept will be the official moniker of OPT-302, which holds fast track designation from the US Food and Drug Administration (FDA).

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.

Belite Bio has completed patient enrollment for a trial evaluating Tinlarebant, which is the first ever treatment for Stargardt Disease.

The companies plant to create a comprehensive resource that provides valuable insights into health outcomes, medication adherence, and the effectiveness of various treatment protocols.

Clearside Biomedical developing a long-acting therapy for the treatment of retinal diseases, including wet AMD.

DAYLIGHT is the first of the company's 3 studies and was a randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of a high-intensity dosing regimen of tarcocimab tedromer.